TipRanks
Clinuvel Pharmaceuticals Limited (CH:UR9)
:UR9
Switzerland Market
UR9
Clinuvel Pharmaceuticals
RESEARCH TOOLSreports

Clinuvel Pharmaceuticals (UR9) Ratios

0 Followers

Clinuvel Pharmaceuticals Ratios

CH:UR9's free cash flow for Q4 2026 was AU$0.35. For the 2026 fiscal year, CH:UR9's free cash flow was decreased by AU$ and operating cash flow was AU$0.52. See a summary of the company’s cash flow.
Ratios
TTM
Jun 26Jun 25Jun 24Jun 23
Liquidity Ratios
Current Ratio
 14.81 14.81 9.66 8.81 7.44
Quick Ratio
 14.45 14.45 9.34 8.39 7.06
Cash Ratio
 1.06 1.06 8.24 7.29 0.94
Solvency Ratio
 1.50 1.48 1.21 1.31 1.05
Operating Cash Flow Ratio
 1.92 1.92 1.51 1.47 1.45
Short-Term Operating Cash Flow Coverage
 94.98 94.98 0.00 0.00 0.00
Net Current Asset Value
AU$ 261.36MAU$ 261.36MAU$ 232.03MAU$ 193.95MAU$ 159.72M
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Debt-to-Equity Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Debt-to-Capital Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.09 1.09 1.13 1.14 1.18
Debt Service Coverage Ratio
 71.47 58.24 9.37 9.26 9.83
Interest Coverage Ratio
 0.00 498.67 10.25 10.78 12.81
Debt to Market Cap
 <0.01 <0.01 0.00 0.00 0.00
Interest Debt Per Share
 0.04 0.04 0.10 0.10 0.08
Net Debt to EBITDA
 -0.45 -0.45 -3.91 -3.25 -0.49
Profitability Margins
Gross Profit Margin
43.11%83.18%83.29%91.23%64.59%
EBIT Margin
43.11%43.11%58.95%62.52%62.27%
EBITDA Margin
44.16%43.72%60.20%63.82%59.20%
Operating Profit Margin
43.11%43.11%48.13%54.44%52.23%
Pretax Profit Margin
50.69%50.69%54.26%57.47%58.19%
Net Profit Margin
36.07%36.07%38.07%40.41%39.08%
Continuous Operations Profit Margin
36.07%36.07%38.07%40.41%39.08%
Net Income Per EBT
71.16%71.16%70.17%70.32%67.15%
EBT Per EBIT
117.59%117.59%112.73%105.57%111.41%
Return on Assets (ROA)
11.45%11.45%13.31%15.42%15.73%
Return on Equity (ROE)
13.00%12.43%15.02%17.55%18.59%
Return on Capital Employed (ROCE)
14.64%14.64%18.70%23.31%24.20%
Return on Invested Capital (ROIC)
10.40%10.40%13.10%16.36%16.22%
Return on Tangible Assets
11.46%11.46%13.32%15.43%15.76%
Earnings Yield
8.37%6.61%6.96%4.57%3.46%
Efficiency Ratios
Receivables Turnover
 4.01 4.01 3.46 3.36 3.53
Payables Turnover
 5.79 12.36 6.23 3.30 9.93
Inventory Turnover
 7.77 2.30 1.80 0.73 2.91
Fixed Asset Turnover
 10.17 10.17 13.33 11.42 27.47
Asset Turnover
 0.32 0.32 0.35 0.38 0.40
Working Capital Turnover Ratio
 0.37 0.38 0.44 0.49 0.54
Cash Conversion Cycle
 74.91 220.35 249.62 499.48 192.08
Days of Sales Outstanding
 91.05 91.05 105.49 108.61 103.53
Days of Inventory Outstanding
 46.95 158.83 202.75 501.57 125.29
Days of Payables Outstanding
 63.09 29.53 58.62 110.70 36.74
Operating Cycle
 138.00 249.88 308.24 610.18 228.82
Cash Flow Ratios
Operating Cash Flow Per Share
 0.74 0.74 0.82 0.73 0.75
Free Cash Flow Per Share
 0.71 0.71 0.81 0.62 0.73
CapEx Per Share
 0.03 0.03 <0.01 0.11 0.02
Free Cash Flow to Operating Cash Flow
 0.96 0.96 0.99 0.85 0.97
Dividend Paid and CapEx Coverage Ratio
 8.99 8.99 14.66 4.61 12.29
Capital Expenditure Coverage Ratio
 23.04 23.04 137.64 6.64 35.92
Operating Cash Flow Coverage Ratio
 19.04 19.04 77.75 42.12 36.92
Operating Cash Flow to Sales Ratio
 0.39 0.39 0.43 0.42 0.47
Free Cash Flow Yield
8.60%6.89%7.85%4.04%4.06%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 11.94 15.12 14.42 21.88 28.87
Price-to-Sales (P/S) Ratio
 4.35 5.45 5.47 8.84 11.28
Price-to-Book (P/B) Ratio
 1.48 1.88 2.16 3.84 5.37
Price-to-Free Cash Flow (P/FCF) Ratio
 11.59 14.52 12.74 24.77 24.62
Price-to-Operating Cash Flow Ratio
 10.95 13.89 12.65 21.04 23.93
Price-to-Earnings Growth (PEG) Ratio
 -2.15 -2.72 5.05 1.36 0.61
Price-to-Fair Value
 1.48 1.88 2.16 3.84 5.37
Enterprise Value Multiple
 9.41 12.02 5.18 10.60 18.56
Enterprise Value
 391.85M 494.25M 296.21M 596.62M 860.59M
EV to EBITDA
 9.44 12.02 5.18 10.60 18.56
EV to Sales
 4.17 5.26 3.12 6.77 10.99
EV to Free Cash Flow
 11.10 14.00 7.26 18.95 23.98
EV to Operating Cash Flow
 10.62 13.39 7.21 16.10 23.31
Tangible Book Value Per Share
 5.48 5.47 4.81 3.97 3.32
Shareholders’ Equity Per Share
 5.48 5.47 4.81 3.98 3.33
Tax and Other Ratios
Effective Tax Rate
 0.29 0.29 0.30 0.30 0.33
Revenue Per Share
 1.89 1.89 1.90 1.73 1.59
Net Income Per Share
 0.68 0.68 0.72 0.70 0.62
Tax Burden
 0.71 0.71 0.70 0.70 0.67
Interest Burden
 1.18 1.18 0.92 0.92 0.93
Research & Development to Revenue
 0.19 0.19 0.08 0.03 0.02
SG&A to Revenue
 0.21 0.21 0.28 0.02 0.02
Stock-Based Compensation to Revenue
 0.00 0.00 0.02 0.07 0.11
Income Quality
 1.09 1.09 1.14 1.04 1.21
Currency in AUD